Revelation Biosciences, Inc. (REVB) Key Metrics
REVB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.9M
- Enterprise value
- −$6.8M
- P/E (TTM)
- 0.1
- Forward P/E
- 0.9
- PEG ratio
- —
- Price / sales
- 2.9
- Price / book
- 0.4
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −0.06
REVB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsREVB returns How much profit the business earns on the capital it uses.
REVB financial health Debt, liquidity and how easily interest is covered.
REVB efficiency & capital use Working capital cycle and where the cash goes.
REVB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
REVB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
REVB cash returned to shareholders
REVB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $3.20 | $88.51 | $2,885.76 | $38,304.00 | $999,996.48 | $999,996.48 | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −131.4% | −264.9% | −3.1% | — | — | −0.4% | — | 12.2% | 9.1% | 5.2% |
| Return on invested capital (ROIC) | — | — | — | — | — | −0.2% | −0.0% | 12.1% | 8.9% | 6.4% |
| Return on assets (ROA) | −97.9% | −159.7% | −1.4% | −287.0% | −31.5% | −0.4% | −0.0% | 1.2% | 0.8% | 0.5% |
| Return on tangible assets | −77.0% | −227.1% | −1.0% | −196.8% | −587.0% | −0.2% | — | 1.1% | 0.8% | 0.5% |
| Free cash flow margin | — | — | — | — | — | — | 42.3% | 37.3% | 31.7% | 22.6% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | 1.18 | 1.49 | 1.32 |
| Financial health | ||||||||||
| Total debt | $746,784 | — | — | $2.9M | $16,752 | — | $174.2M | $124.6M | $108.4M | $116.5M |
| Cash & short-term investments | $10.7M | $6.5M | $12.0M | $5.3M | $1.3M | $537,021 | $147.1M | $136.4M | $72.2M | $111.5M |
| Net debt | −$10.0M | −$6.5M | −$12.0M | −$2.3M | −$1.3M | −$537,021 | $27.1M | −$11.8M | $36.2M | $5.0M |
| Debt / equity | 0.08 | — | — | 2.77 | — | — | — | 0.47 | 0.58 | 0.69 |
| Debt / assets | 0.06 | — | — | 0.53 | 0.01 | — | 7,682.81 | 0.05 | 0.05 | 0.06 |
| Current ratio | 5.41 | 3.43 | 2.18 | 1.22 | 0.89 | 0.19 | — | 0.07 | 0.04 | — |
| Quick ratio | 5.41 | 3.43 | 2.18 | 1.22 | 0.89 | 0.19 | — | 0.07 | 0.04 | — |
| Interest coverage | — | — | — | -310.8 | -286.2 | — | — | — | — | — |
| Working capital | $8.8M | $4.7M | $6.6M | $962,320 | −$229,611 | −$2.8M | $154.8M | −$1.98B | −$1.72B | — |
| Invested capital | −$1.1M | −$1.8M | −$5.3M | −$1.3M | −$1.4M | $67.3M | $27.1M | $253.1M | $224.5M | $173.7M |
| Tangible asset value | $8.9M | $4.7M | $6.6M | $1.1M | −$99,470 | $67.8M | −$29.7M | $234.4M | $157.1M | $137.5M |
| Net current asset value | $8.1M | $4.7M | $6.6M | $962,320 | −$229,611 | −$5.7M | $154.8M | −$2.05B | −$1.83B | — |
| Capital allocation | ||||||||||
| Dividends paid | $5.95B | — | — | $7.7M | — | — | — | — | — | — |
| Share buybacks (net) | — | $0 | $5,000 | $7.7M | — | — | — | — | — | — |
| Capex / revenue | — | — | — | — | — | — | 0.5% | 1.0% | 1.1% | 1.2% |
| Capex / operating cash flow | — | — | — | — | — | — | 1.3% | 2.6% | 3.3% | 5.0% |
| Capex / depreciation | 0.00 | 0.69 | 0.00 | 0.00 | 7.86 | 0.00 | 0.30 | 0.58 | 0.50 | 0.68 |
| SG&A / revenue | — | — | — | — | — | — | 37.9% | 39.9% | 42.3% | 44.0% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | 27.7 | 27.3 | 26.7 | 37.2 |
| Days payables outstanding | 9,180.5 | 14,009.7 | 13,945.6 | 5,248.0 | 3,858.0 | — | 108.8 | — | — | — |
| Cash conversion cycle (days) | — | — | — | — | — | — | -81.1 | — | — | — |
| Receivables turnover | — | — | — | — | — | — | 13.20 | 13.38 | 13.65 | 9.81 |
| Payables turnover | 0.04 | 0.03 | 0.03 | 0.07 | 0.09 | — | 3.36 | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.04 | 0.04 | 0.03 |
| Average receivables | — | — | — | — | — | — | $7.3M | $6.4M | $5.4M | $5.0M |
| Average payables | $680,561 | $1.1M | $957,052 | $575,233 | $731,081 | $1.2M | $1.5M | $1.1M | $913,000 | $897,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 131,145.5% | 1.2% | 1.5% | 1.7% |
Computed from REVB's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
REVB valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.1 and the forward P/E is 0.9. Revelation Biosciences earned a return on equity of −131.4% in fiscal 2025. It ended the year with $0.7 million of debt and $10.7 million in cash and short-term investments, a net cash position of $10.0 million. It returned $6.0 billion to shareholders: $6.0 billion in dividends and $0 in share buybacks.
See the REVB income statement, the REVB chart for price history, or the REVB stock overview for the latest quote and news.
REVB key metrics FAQ
What is Revelation Biosciences's P/E ratio?
Revelation Biosciences's trailing P/E ratio is 0.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 0.9. At the end of fiscal 2025 it was —.
What is Revelation Biosciences's return on equity?
Revelation Biosciences's return on equity (ROE) was −131.4% in fiscal 2025: net income of -$8.9 million on average shareholders' equity of $6.8 million.
How much debt does Revelation Biosciences have?
Revelation Biosciences had total debt of $0.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.08 and more cash than debt.
What is Revelation Biosciences's current ratio?
Revelation Biosciences's current ratio was 5.41 at the end of fiscal 2025: current assets were 5.41 times current liabilities.